2025 Japan Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 Japan Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's anti-obesity drugs market are Chugai Pharmaceutical, Novo Nordisk, Eli Lilly, and Amgen. Chugai, partly owned by Roche, is developing orally administered obesity treatments including Orforglipron and GYM329, aiming to provide alternatives to injectable drugs with fewer side effects; its market value surged to 12 trillion yen due to investor optimism. Novo Nordisk leads with semaglutide (Wegovy), the largest revenue-generating GLP-1 agonist in Japan's expanding market, while Eli Lilly’s tirzepatide (Zepbound) shows the fastest growth in the segment. Amgen is advancing its obesity pipeline with MariTide, a monthly injectable anti-obesity drug, reinforcing its position in the biopharmaceutical space.
Japan’s anti-obesity medication market generated approximately USD 366.2 million in 2023 and is forecasted to reach USD 4.5 billion by 2030, growing rapidly at a CAGR of 43.2%. Novo Nordisk and Eli Lilly dominate with GLP-1 drugs like Wegovy and Zepbound, critical drivers of market growth, while Chugai focuses on innovative oral therapies. Amgen's pipeline complements these with new injectable formulations. Other key players globally present in Japan include Pfizer, Boehringer Ingelheim, and GlaxoSmithKline, contributing to a dynamic and competitive landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's anti-obesity drugs market are Chugai Pharmaceutical, Novo Nordisk, Eli Lilly, and Amgen. Chugai, partly owned by Roche, is developing orally administered obesity treatments including Orforglipron and GYM329, aiming to provide alternatives to injectable drugs with fewer side effects; its market value surged to 12 trillion yen due to investor optimism. Novo Nordisk leads with semaglutide (Wegovy), the largest revenue-generating GLP-1 agonist in Japan's expanding market, while Eli Lilly’s tirzepatide (Zepbound) shows the fastest growth in the segment. Amgen is advancing its obesity pipeline with MariTide, a monthly injectable anti-obesity drug, reinforcing its position in the biopharmaceutical space.
Japan’s anti-obesity medication market generated approximately USD 366.2 million in 2023 and is forecasted to reach USD 4.5 billion by 2030, growing rapidly at a CAGR of 43.2%. Novo Nordisk and Eli Lilly dominate with GLP-1 drugs like Wegovy and Zepbound, critical drivers of market growth, while Chugai focuses on innovative oral therapies. Amgen's pipeline complements these with new injectable formulations. Other key players globally present in Japan include Pfizer, Boehringer Ingelheim, and GlaxoSmithKline, contributing to a dynamic and competitive landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
